China’s NMPA cleared Sichuan Biokin to begin clinical trials of [177Lu]‑BL‑ARC001, advancing a radioligand candidate into the clinic. The clearance comes amid a broader revival of radioligand therapy (RLT) for neuroendocrine and other solid tumors; recent reviews highlight RLT’s mechanisms and evolving clinical applications for gastroenteropancreatic neuroendocrine tumors. Regulatory greenlights and expanding clinical evidence are accelerating industry investment in targeted radiopharmaceuticals, linking diagnostic and therapeutic pipelines and creating commercial opportunities in both clinical and manufacturing arenas.